Pipeline

Core Global Development Pipeline of ONO

Oncology

As of 26 April, 2022

Product Name Mechanism Target Disease Development Stage Country /
Region
Licensor
1 2 3 Filing Approval
ONO-4059 BTK inhibitor Primary central nervous system lymphoma           JP・KR・TW In-house
          US
Waldenström macroglobulinemia/Lymphoplasmacytic lymphoma           JP
ONO-7475 Axl/Mer inhibitor Acute leukemia           US In-house
Solid tumor ★           JP
EGFR mutation-positive non-small cell lung cancer           JP
ONO-4685 PD-1 x CD3 bispecific antibody T-cell lymphoma           US In-house
ONO-4578 PG receptor (EP4) antagonist Solid tumor・Gastric cancer ★           JP In-house
Colorectal cancer ★           JP
Pancreatic cancer ★           JP
Non-small cell lung cancer ★           JP
Hormone receptor-positive, HER2-negative breast cancer           JP
ONO-7914 STING agonist Solid tumor ★           JP In-house

★Combination with Nivolumab

Other than oncology

As of 26 April, 2022

Product Name Mechanism Target Disease Development Stage Country /
Region
Licensor
1 2 3 Filing Approval
ONO-4059 BTK inhibitor Pemphigus           JP In-house
Generalized scleroderma           JP
ONO-2910 Enhancement of Schwann cell differentiation Diabetic polyneuropathy           JP In-house
ONO-4685 PD-1 x CD3 bispecific antibody Autoimmune disease           EU In-house
          JP In-house
ONO-2808 S1P5 receptor agonist Neurodegenerative disease           EU In-house
          JP
ONO-7684 FXla inhibitor Thrombosis           EU In-house
ONO-2909 PG receptor (DP1) antagonist Narcolepsy           JP In-house